NEW HOPE

IN BLADDER CANCER TREATMENT

 
 

ABOUT US

Vessi Medical is developing a new approach in the treatment of Non Muscle Invasive Bladder Cancer (NMIBC).

The company uses surface cryotherapy, a method that utilizes extreme cold, to freeze and destroy abnormal tissue.

VESSI MEDICAL
 

THE OPPORTUNITY

There is an 80% chance of recurrence with the current standard of care

Transurethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. A costly, invasive surgical procedure, TURBT is performed in a hospital under general anesthesia, with significant complications. Moreover, in up to 80% of cases the cancer returns, and that results in multiple repeat procedures which further reduce patients’ quality of life. 

Vessi’s initial target is the

$1.2 billion NMIBC market

4

TH

Bladder cancer is the fourth most common cancer in men

75%

75% of all bladder cancers

are NMIBC

2M

2 million suffer globally

from NMIBC

300K

300,000 new cases every year!

NMIBC is defined as a cancer on the surface of the inner lining of the bladder. Physical symptoms often include problems urinating, pain and blood in the urine, or sexual dysfunction; however, it may also affect mental health and lead to a significant decrease in quality of life.

 

Vessi freezes the tumor; eliminates the cancer

Vessi's minimally invasive solution for NMIBC provides a new, first-line, therapeutic alternative to surgery. The company's bladder-specific cryotherapy reduces the cost and eliminates the complications associated with TURBT.

       Successfully ablates unwanted tissue

       Eliminates risk of dispersed cancer cells

       Minimizes harm to bladder functionality

       Reduces complications

       Improves quality of life

OUR SOLUTION

THE VESSI SYSTEM

The Vessi system consists of a standalone console and a disposable device that is inserted transurethrally into the bladder.

PATIENT

HEALTH

CARE SYSTEM

Advantages

Patent-pending, bladder specific

cryo-spray technology

Balances the ideal cooling temperature and pressure for targeted cell destruction, yet protects the bladder

Designed for the specific environment of the bladder

Intuitive “same style”

TURBT procedure

for more efficient user adoption

Two patents-pending: national phase and PCT

PHYSICIAN

PATIENT

PHYSICIAN

HEALTH

CARE SYSTEM

Publications

TEAM

Eyal Kochavi,

Founder & CEO

Seasoned medical device manager with vast cryotherapy experience; prior positions with Motus GI, Galil Medical, Given Imaging; MSc, MBA, Technion Israel institute of Technology

Moti Simchon,

Cryogenics Expert

Years of experience in pneumatics, fine mechanics, and cryogenics; prior position in the defense industry

Tamir Shavit,

Lab Manager

Hands-on experience in prototyping and manufacturing at medical device start-up companies; prior position at Stimatix GI Ltd.

(now part of B. Braun)

Advisory Board

Prof. Gilad E. Amiel,

Scientific Advisor

Chairman, Department of Urology, Rambam Health Care Campus, Israel; adjunct Associate Professor of Urology, Baylor College, Houston, Texas; former President of the American Association for Cancer Education (AACE)

Prof. Yair Lotan,

Scientific Advisor

Professor of Urology, Chief of Urologic Oncology, and holder of Professorship in Urology at UT Southwestern Medical Center; Medical Director of the Urology Clinic at Parkland Health and Hospital System

Doron Birger,

Business Advisor

Former President and CEO, Elron (NASDAQ-ELRN); former Chairman Given Imaging (NASDAQ-GIVN); chairman and board member of numerous medical device companies

 
 

CONTACT US

For Information

Vessi Medical
Misgav Industrial Park
Misgav, Israel

 

 

 


Eyal Kochavi, CEO & Founder
Mail: eyal@vessimed.com
Telephone: +972.52.523.5454

  • White LinkedIn Icon
 

References

1. Babjuk M. Transurethral resection of non–muscle-invasive bladder cancer. European Urology Suppl 2009 8(7):542-548.
2. Traxer O1, Pasqui F, Gattegno B, Pearle MS. Technique and complications of transurethral surgery for bladder tumours. BJU Int. 2004 Sep;94(4):492-6.

3. Kamat AM, Bağcıoğlu M, Huri E. What is new in non-muscle-invasive bladder cancer in 2016 Turk J Urol. 2017 Mar; 43(1): 9–13.

4. Schmidt S et al. Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study. Urol Oncol. 2015 Jan;33(1):19.e7-19.e15. doi.

Vessi Medical logo copy.png